VTRS

SELL

Viatris Inc.

Healthcare · Rank #475 · Analyzed Apr 20, 2026

$14.68

Current Price

$0.00

Intrinsic Value

0.0%

Upside/Downside

1/10

Score

0.8/5

Quality

Analysis Summary

Valuation Consensus1/2 methods agree

Quality Score0.8/5.0

Framework RatingSELL

Price vs Intrinsic ValueOvervalued by 0.0%

Fair Value Range

Low$10.11

Base (IV)$0.00

High$72.02

Entry Points

Conservative$10.11

Moderate$29.06

Aggressive$48.02

⚠️ Warnings

Biotech/pharma: negative margins from R&D — using forward estimates
Upside capped: raw 391% exceeds 200% — valuation unreliable

Quality & Moat Breakdown

Return on Equity-21.1% → 0/1.0

Debt LevelD/E 100 → 0/1.0

Revenue QualityGrowth 1.9%, margin Δ-7.7% +recovery → 0.5/1.0

Moat Strength1.5/5 → 0/1.0

Profit Margins-24.6% → 0.25/1.0

Methodology

This analysis uses a unified valuation framework combining three methods — Discounted Cash Flow (3-scenario), Earnings Power Value, and Asset Valuation — with a quality scoring overlay. A stock needs 2/3 valuation methods to agree and a quality score ≥ 3.5/5 for a BUY rating.

Learn how this framework works →

This is a personal analysis tool, not financial advice. Do your own research before making investment decisions.